We are more than a tech transfer office. We are a medical innovations powerhouse. Cleveland Clinic Innovations brings the best ideas from the brightest minds in medicine to patients around the world. We connect inventors and their ideas with strategic industry partners to create products that transform the future of healthcare. Cleveland Clinic is changing healthcare for patients around the world. https://39682636.hs-sites.com/bio-home | x | Cleveland Clinic Innovations (CCI) is dedicated to turning caregiver-inspired ideas into medical breakthroughs that meaningfully improve patient lives. Since 2000, our team has transformed over 900 technologies into licensed products, secured more than 2,800 patents, and launched over 100 spin-off companies, achieving 28 successful exits. Our multidisciplinary team works side-by-side with clinicians, researchers, and industry to guide innovations through every stage, from concept to licensing, startup formation, clinical validation, and scaling. We’re more than a technology transfer office, we’re strategic partners in transforming healthcare innovation. Whether it’s harnessing AI for diagnostics, pioneering digital health solutions, developing novel therapeutics, or creating advanced drug delivery systems, we ensure that innovative ideas become practical solutions impacting patient care globally. Technologies available for licensing include: · Digital Health · Drug Delivery · Diagnostics · Therapeutics · Research Tools What Makes Cleveland Clinic Innovations Unique? · Direct clinician and researcher access for rapid, real-world healthcare insights. · Robust clinical validation and real-world data-driven innovation within a globally recognized health system. · Comprehensive IP management, strategic licensing expertise, and proven healthcare startup incubation. Why partner with Cleveland Clinic Innovations? · Expert guidance through healthcare startup creation, technology transfer, and commercialization pathways. · Integrated access to world-class clinical, regulatory, and research infrastructure. · Global presence supporting innovations across markets (U.S., London, Abu Dhabi, Canada). Together, we can accelerate healthcare innovation and create meaningful patient impact. Explore our technologies and partner with us: https://my.clevelandclinic.org/innovations
Cincinnati Children’s Hospital Medical Center
Cincinnati Children’s Innovation Ventures as well as staff from Cincinnati Children’s Applied Gene and Cell Therapy Center will be onsite.
Cfm Oskar Tropitzsch GmbH
Cfm Oskar Tropitzsch GmbH assists the chemical, pharmaceutical and biotechnological industry in sourcing and producing chemical specialties. The core of our work is to supply the product which our customer is looking for – with the right documentation, the correct quantity from mg to mt and proper quality and this not only for a one shot business but to support projects from RnD state up to commercial production. To achieve these challenging goals Cfm Oskar Tropitzsch GmbH uses its excellent knowhow and worldwide network of qualified suppliers. Finding the best solution! …it’s not just a sentence – it’s our mission! | Cfm Oskar Tropitzsch GmbH assists the chemical, pharmaceutical and biotechnological industry in sourcing and producing chemical specialties. The core of our work is to supply the product which our customer is looking for – with the right documentation, the correct quantity from mg to mt and proper quality and this not only for a one shot business but to support projects from RnD state up to commercial production. To achieve these challenging goals Cfm Oskar Tropitzsch GmbH uses its excellent knowhow and worldwide network of qualified suppliers. Finding the best solution! …it’s not just a sentence – it’s our mission! Our product categories are: -ADC-Payloads -API`s -Contract Manufacturing / Contract Fermentation within Europe/US -Diagnostic Reagents like e.g. DTT -Excipients – Contract Manufacturing of Excipients (g-kg) -Metals & Metal Compounds -Peptide Synthesis -Pytochemicals -Small Molecules (Fermentation Products)
Celltrion, Inc.
A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business. | Celltrion is a leading global biopharmaceutical company dedicated to improving the health and well-being of patients. We have presented a new paradigm to the global biologics market with the launch of the world’s first monoclonal antibody biosimilar. Celltrion will continue to pursue its goal in promoting the health and well-being of patients.
Cellex Cell Professionals
Cellex is an end-to-end CDMO based in Cologne, Germany with 10+ years’ experience in manufacturing autologous & allogenic cell and gene therapy (CGT) products. We support customers from preclinical development stages through clinical manufacturing to commercialization. Currently, Cellex is manufacturing several final drug products (FDPs) and cellular intermediates (ITMs) including commercial products. In addition, Cellex offers customized starting materials from healthy donors and patients affected by specific conditions for research, clinical and commercial purposes as well as GDP-compliant logistics services for cellular materials. | Cellex is a European-based end-to-end CDMO with deep expertise in the development and GMP manufacturing of autologous and allogeneic cell and gene therapy (CGT) products. With a demonstrated GMP track record of more than 20 years, Cellex supports partners from preclinical development through clinical manufacturing to commercialization, serving top 10 pharma companies, leading biotech companies, innovative start-ups, and academic centers worldwide. Cellex operates more than 26,500 sqft of GMP manufacturing facilities and holds multiple manufacturing licenses covering cellular intermediates and final drug products. The company is involved in the manufacture of three approved CAR-T therapies and has produced over 9,000 CGT/ATMP batches. Through its own apheresis center and donor database, Cellex has performed more than 50,000 cell collections for CGT and stem cell transplantation, and provides a broad portfolio of starting materials – including leukopaks, mobilized leukopaks, bone marrow, and whole blood – from both healthy donors and patients affected by specific diseases, for R&D, clinical, and commercial use. All collections are performed under GMP conditions and supplied globally. EU QP services, consulting, and GMP audits of apheresis centers worldwide complement Cellex’s offering, which is characterized by scientific expertise, quality, and flexibility.
Cellipont Bioservices
Cellipont Bioservices is a cell therapy CDMO with experience in the development and manufacturing of cell therapies. Our leaders have played an instrumental role in shaping the cell therapy development and manufacturing methods and technologies. Our technically strong team has been recognized by our partners for their ability to manufacture and release products successfully. Cellipont is committed in helping our partners to expand patient access to life-changing medicines through best-in-class development, analytical and manufacturing capabilities. Cellipont Bioservices has a team of subject-matter-experts with extensive experience in the translation of your process from benchtop to bedside. Our team has hands on experience within autologous and allogenic cell therapies, and native & genetically modified cells. We have proven in-house scientific and manufacturing expertise for all phases of clinical products for our range of clients from Pre-Clinical to Late Phase commercialization. Our extensive experience spans across multiple product areas, including: CAR-T/TCR-T DCs Fibroblasts NK MSCs HSCs TIL Cell Banking (MCB, WCB) Feeder Cell Banks Cellipont Bioservices has very deep technical experience, including 18,000+ tissue samples and more than 1,800 primary cell cultures. With decades of experience at advanced therapy service companies large and small, our leadership team is guiding Cellipont Bioservices’ growth with deep knowledge of what it takes to succeed in this space. Cellipont cell therapy scientists in lab Located in The Woodlands, Texas right outside of Houston, Cellipont Bioservices facilities and quality systems are GMP-compliant. Cellipont Bioservices is privately held. Our core investor, Great Point Partners, is a dedicated healthcare-focused investment firm with an extensive track record in successfully building biologics services businesses. | Cellipont Bioservices firmly believes that cell therapies deserve personalized and dedicated support. Our team is comprised of tenured experts within the cell therapy space, working on advancing a wide spectrum of cell modalities from CAR-T, iPSC to DCs and MSCs. Located in The Woodlands, Texas, we are strategically located near some of the best medical centers in the world. We strive to lead alongside our partners from the forefront of innovation, translating cutting-edge processes from lab to bedside. | Cellipont Bioservices is a contract development and manufacturing organization (CDMO) dedicated exclusively to advanced therapies, supporting biotech and biopharma companies developing cell therapies from preclinical stages through commercial supply. The company provides integrated development, analytical, and GMP manufacturing solutions designed to accelerate clinical timelines while maintaining regulatory readiness and product quality. The organization has commercial manufacturing experience, and its facility is designed to support both early clinical development and commercial programs. The organization specializes in autologous and allogeneic cell therapy modalities, including CAR-T, TCR-T, NK, stem cell, and other engineered immune cell products. Its services are structured to bridge the gap between early process concepts and scalable, regulatory-compliant manufacturing workflows, enabling sponsors to transition efficiently from research into clinical production and long-term commercial supply.
C Ray Therapeutics (Chengdu) Co., Ltd.
C Ray Therapeutics Group operates an R&D center in Shanghai, focused on proprietary pipeline development. This covers early discovery, process development, clinical research, and registration. The company has established over 10 development pipelines targeting solid tumors, utilizing isotopes such as Cu-64, Lu-177, and Ac-225, with a variety of ligands, including small molecules, peptides, and modified antibodies. Several pipelines feature globally innovative molecules with independent intellectual property rights. | C-Ray Therapeutics is dedicated to delivering end-to-end solutions for innovative radiopharmaceuticals to clients around the world. Our services span process development, quality research, preclinical evaluation, IND Enabling, clinical supply, and commercial scale cGMP production, all backed by a reliable, robust logistics network. As of 2024, we have raised over USD 187 million in total funding. C-Ray has 28,000 square-meter, state-of-the-art, world class R&D and cGMP manufacturing facilities with the highest Class A Radiation Safety License, allowing commercial scale operational volume of over 30+ radioisotopes. GLP-like preclinical study center has both small and large lab animal use permit with animal feeding and administration lab, animal PET/CT for imaging, gama counter and pathology lab for biodistribution and dosimetry analysis. C-Ray has successfully delivered and continues to operate 70 CRDMO projects, including 50 preclinical and molecular imaging CRO projects and 24 CDMO projects. Among these, 5 have entered the IND and IND-enabling stages, 16 have advanced to investigator-initiated trials (IITs), and 5 have entered the clinical supply stage, with 2 of them successfully progressing to a Phase III clinical study. The company has achieved comprehensive coverage of all critical links across the entire radiopharmaceutical R&D and manufacturing chain. As a dedicated CRDMO partner in radiopharmaceuticals, one of our core strengths is a stable, diversified supply of radionuclides. We are actively developing high-quality domestic sources while playing a leading role in integrating and fortifying the global supply chain—most notably securing access to challenging isotopes such as Ac-225. To date, we have supported the development of 19 Ac-225–labeled projects.
BSP PHARMACEUTICALS S.p.A
BSP Pharmaceuticals is a CDMO, technologically developed to meet needs of groundbreakers and specialized in manufacturing Oncology and Immunotherapy drug, including autoimmune disease, immunotherapy & CNS among others, with a specific focus on innovative compounds. With full containment facility, applying the most advanced and safe technologies, BSP can offer capabilities with a wide range of batch sizes providing flexibility to sustain preclinical, clinical and commercial manufacturing. The facility is designed to handle small molecules and large molecules, including ADCs (from Conjugation to Fill Finish), mAbs (including bi-specific), synthetic peptides, oligonucleotides, lipidic nanomedicine Production area includes: – a plant dedicated to Cytotoxic compounds, small and large molecules, (OEL